Overview

An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Patients With Primary Hyperoxaluria Type 1

Status:
Active, not recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of lumasiran in patients with Primary Hyperoxaluria Type 1.

Phase:

Phase 2

Details

Lead Sponsor:

Alnylam Pharmaceuticals